Cantargia AB Q3 2022 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Luisa Morgavo - Amin Financial - Analyst : Hi. This is Luisa dropping in for Sebastian from Kempen. Thank you for taking our question. I have a few. So first, just to start off, you announced a number of changes in the pipeline, and we were wondering how will this impact the current spending and do you anticipate a significant reduction in R&D for the next year?

Question: Luisa Morgavo - Amin Financial - Analyst : Clear. And now you also have some more knowledge on the nadumolimab compound, and I was wondering, do you maybe have any idea on what drives the synergy with the platinum-based chemotherapy?

Question: Luisa Morgavo - Amin Financial - Analyst : Just a final question regarding the business development progress and maybe having a partnership for the randomized non-small cell lung cancer trial. Do you have -- yeah, can you indicate something about where you are now at this point with the partnership discussions? And what topics are these discussions centered on? And what would be, in your view, the most ideal setting to test the compound CANFOUR?

Question: Luisa Morgavo - Amin Financial - Analyst : Yes.

Question: Luisa Morgavo - Amin Financial - Analyst : Okay. Thank you.

Question: Soo Romanoff - Edison Group - Analyst : Hi. Thank you for the presentation. G÷ran, I have a few questions here. It was nice to see the positive momentum in the readouts and the patient enrollment. Could you provide an update on the anticipated timeline for the planned randomized trial in pancreatic and non-small cell lung cancer and any details on what randomized trials in non-small cell lung cancer might look like?

Question: Soo Romanoff - Edison Group - Analyst : All right. What about -- what results would you be looking for in the ongoing CANFOUR trial to support further randomized trials in non-small cell lung cancer patients?

Question: Soo Romanoff - Edison Group - Analyst : Okay. That's great. So the last one it's a little bit of a follow-on to that first set of questions here. There was, I think, we -- the focus has really helped on extending the cash runway, but we didn't really see all that come through which is kind of what your answer implied. But what approximately are the operating expenses that we should kind of look at on a run rate basis and maybe approximate timing? Or maybe, we just see it all in the next quarter? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. NOVEMBER 10, 2022 / 2:00PM, CANTA.ST - Q3 2022 Cantargia AB Earnings Call

Question: Soo Romanoff - Edison Group - Analyst : No, no. That's all.

Question: Soo Romanoff - Edison Group - Analyst : Yeah. No, thank you very much for taking my questions. Nice quarter.

Question: Richard Ramanius - Redeye AB - Analyst : Hello. Good afternoon. I want to start with the trial in breast cancer TRIFOUR. So, first of which, would that be a potentially pivotal trial that you will initiate the randomized trial? And secondly, who will finance this trial, or do you finance all by yourselves?

Question: Richard Ramanius - Redeye AB - Analyst : Okay. And also, I had a question about CAPAFOUR. Is there any reason for believing that FOLFIRINOX would work differently than NAPOX in pancreatic cancer? I mean, would we -- if any, reason we should expect any different outcome in this trial compared with CANFOUR? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. NOVEMBER 10, 2022 / 2:00PM, CANTA.ST - Q3 2022 Cantargia AB Earnings Call

Question: Richard Ramanius - Redeye AB - Analyst : No, thank you. Those are my questions.

Question: Arvid Necander - Carnegie Investment Bank AB - Analyst : Good afternoon. Thanks for taking my questions. Just a quick follow-up, first of all, on the CAPAFOUR study. Can you say anything about the signals you've seen so far? Have you observed any responses or early tumor shrinkage in the study?

Question: Arvid Necander - Carnegie Investment Bank AB - Analyst : Okay, fair enough. And then just a second question on CAN10, which is starting to look quite promising. The only other molecule targeting IL1RAP that I'm aware of at least was recently out licensed to a biopharma player aiming to evaluate it in autoimmune disease. How does your partnering strategy look like for this asset? When are you targeting a deal for this asset? And what do you believe you need to show to achieve this?

Question: Arvid Necander - Carnegie Investment Bank AB - Analyst : Okay, fair enough. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. NOVEMBER 10, 2022 / 2:00PM, CANTA.ST - Q3 2022 Cantargia AB Earnings Call

Question: Arvid Necander - Carnegie Investment Bank AB - Analyst : I'll just --

Question: Arvid Necander - Carnegie Investment Bank AB - Analyst : Right, fair enough. Now I guess my question was, I mean, with nadunolimab, I think the target was to license the asset after having established a proof of concept or completed Phase 2 trials. So I remember right, at least, initially when the company was founded. So I was wondering if the strategy looked -- if you had a different strategy for this asset. But fair enough, we'll have to wait and see. Those are all my questions. Thanks.

Question: Sten Westerberg - Analysguiden - Analyst : Yes, hello. Thank you for taking my questions. My first question, you seem to put a lot of effort now into differentiating your molecule, your dual-acting mode of action compared to single-binding substances such as canakinumab. The question I would have is, is it due to some kind of change in attitude from the industry that you are holding discussions with?

Question: Sten Westerberg - Analysguiden - Analyst : Okay, so it's fair to say that your discussions with the pharma industry has changed in a way following the [canaki] results?

Question: Sten Westerberg - Analysguiden - Analyst : Yes, yes. Last question. Regarding the FOLFIRINOX combination, is it possible to, at this point in time, include FOLFIRINOX in the PanCAN study before presenting the results from the CAPAFOUR study?

Question: Sten Westerberg - Analysguiden - Analyst : Okay, thank you. That concludes my questions.